Download now to read this new Guide from sponsors Apconix. Cardiac safety doesn’t stop with hERG. When it comes to cardiac safety, an integrated approach supports informed decision-making. Discover the importance of the four nonclinical cardiac safety assessments Understand the benefits of each assessment Develop a comprehensive cardiac safety evaluation… Read More
Discover how VOLTA Scanner is transforming cardiac safety testing. This Whitepaper from Lumencor describes an optophysiology instrument, supporting stable, fast, high-resolution toxicity testing and drug development. Download to learn how: VOLTA detects early-after-depolarisations (EADs), and predicts QT/QRS risk Optogenetic pacing improves assay precision Automated, HPT optophysiological screening streamlines… Read More
VOLTA Scanner is transforming cardiac safety testing. This whitepaper describes an optophysiology instrument, supporting stable, fast, high-resolution toxicity testing and drug development. Download to learn how: VOLTA detects early-after-depolarisations (EADs), and predicts QT/QRS risk Optogenetic pacing improves assay precision Automated, HPT optophysiological screening streamlines decisions… Read More
Serca Pharmaceuticals, a cardioprotection company that is developing 13-M, a novel first in class treatment for minimising tissue damage that occurs with blood reperfusion post myocardial infarction (MI) and stenting, has presented data on a novel approach to modulate the beta-adrenergic receptor-cAMP protein kinase A (PKA) signalling pathway that… Read More
